Axsome Therapeutics Azioni (NASDAQ: AXSM)

Axsome Therapeutics (NASDAQ:AXSM) Azioni

AXSOME THERAPEUTICS INC

Axsome Therapeutics

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics Inc

Oppenheimer analyst Matthew Hershenhorn initiates coverage on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform rating and announces Price Target of $185.

News

Price Target

Initiation

Analyst Ratings

AXSM

Oppenheimer Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $185

Axsome Therapeutics Announced Presentations From Three Of Its Innovative Neuroscience Programs At The American Society Of Clinical Psychopharmacology 2025 Annual Meeting, Being Held From May 27-30 In Scottsdale, Arizona

Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">lymphopoietin) and IL-13</a>.
Teva has an exclusive license to develop BD9 for TH2-driven inflammatory diseases such as <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45615937/teva-and-biolojic-design-initiate-ind-enabling-studies-of-bd9-a-multibody-designed-to-explore-the-" rel="noreferrer noopener">atopic dermatitis and asthma</a>.&nbsp;
By simultaneously blocking two key drivers of TH2-driven inflammation, BD9 can potentially improve outcomes for patients with conditions such as atopic dermatitis and asthma, where current treatments fall short.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" target="_blank" rel="noreferrer noopener">Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum</a>
The initiation of IND-enabling studies marks a critical milestone in translating this scientific innovation into a potential therapeutic option. It will pave the way for clinical trials and ultimately bring hope to underserved patient populations.
Under the terms of their agreement, Teva is developing BD9 worldwide.
In exchange, Biolojic is eligible to receive milestone payments based on the achievement of certain pre-clinical, clinical, regulatory, and commercial milestones, including the initiation of IND-enabling studies.
In May, the U.S. Food and Drug Administration (FDA) approved&nbsp;Teva and&nbsp;Alvotech's&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic&nbsp;Johnson &amp; Johnson's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Stelara (ustekinumab)</a>.
In January, The U.S. Food and Drug Administration (FDA) issued a warning regarding the risk of anaphylaxis, a rare but severe allergic reaction associated with glatiramer acetate, a medication used to treat relapsing <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43174108/fda-warns-of-severe-allergic-reaction-risk-with-tevas-multiple-sclerosis-drug" rel="noreferrer noopener">forms of multiple sclerosis (MS)</a>.
Glatiramer acetate, sold under the brand name Copaxone by&nbsp;Teva and as generics like Glatopa, is an injectable medication designed to reduce the frequency of MS relapses.
In February, Axsome Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) signed a settlement agreement with&nbsp;Teva Pharmaceuticals.
The settlement resolves all patent litigation related to Axsome's Auvelity (dextromethorphan HBr –&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">bupropion HCl) product</a>.
Auvelity is approved in the U.S. for major depressive disorder.
The litigation resulted from Teva submitting an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Auvelity in the U.S. before the expiration of applicable Axsome patents.
Price Action: TEVA stock is up 6.01% at $17.98 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

Contracts

Movers

Trading Ideas

General

ALVO

TEVA

Why Is Teva Stock Trading Higher On Tuesday?

Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates (Hetero) resolving patent litigation related to Axsome's product SUNOSI&#xAE; (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hetero of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. Under the terms of the settlement agreement, Axsome will grant Hetero a license to sell its generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.
As required by law, Axsome and Hetero will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Similar patent litigation brought by Axsome against other parties related to SUNOSI remains pending in the U.S. District Court for the District of New Jersey.

Axsome Therapeutics Enters Into Settlement Agreement With Hetero Labs And Certain Of Its Affiliates Resolving Patent Litigation Related To Axsome's Product SUNOSI

Across the recent three months, 16 analysts have shared their insights on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Axsome Therapeutics, revealing an average target of $182.31, a high estimate of $216.00, and a low estimate of $153.00. Witnessing a positive shift, the current average has risen by 4.66% from the previous average price target of $174.20.
<img src="https://www.benzinga.com/files/images/story/2025/1747918822_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Axsome Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$193.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$216.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$212.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Axsome Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>About Axsome Therapeutics</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Understanding the Numbers: Axsome Therapeutics's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Axsome Therapeutics's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 61.95%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -48.91%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Axsome Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -107.81%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Axsome Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.2%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.97, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $180 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target

Axsome Therapeutics Enters $570M Term Loan And Revolving Credit Facility With Blackstone

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and lowers the price target from $200 to $180.

HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Lowers Price Target to $180

Wells Fargo analyst Cerena Chen maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Overweight and raises the price target from $160 to $165.

Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $165

Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $160 to $162.

Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $162

Axsome Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $119.87 million.</a>
Auvelity (oral antidepressant) net product sales for the quarter were $96.2 million, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45190347/axsome-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-update" rel="noreferrer noopener">up 80% year over year</a>.
Approximately 167,000 prescriptions were written for Auvelity in Q1 of 2025. This represents an increase of 76% compared to the same period in 2024 and an increase of 5% compared to the fourth quarter of 2024.
Sunosi, a sleep disorder medicine, generated net product revenues of $25.2 million, up 17%.
Approximately 46,000 prescriptions were written for Sunosi in the U.S., representing an increase of 12% compared to the same period in 2024, but a decrease of 5% compared to the fourth quarter of 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44587826/axsomes-solriamfetol-fails-primary-goal-in-depression-study-but-shows-improvements-in-associated-sleep-disorder" rel="noreferrer noopener">Axsome&#8217;s Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder</a>
The company reported an adjusted net loss of 68 cents.
Net loss for the first quarter of 2025 was $59.4 million, or $1.22 per share. Compare that to a net loss of $68.4 million, or $1.44 per share, for the comparable period in 2024.
The net loss in the first quarter of 2025 includes $26.2 million in non-cash charges, primarily $23.3 million in stock-based compensation expenses.
FDA Approval: The FDA approved Axsome Therapeutics&#8217; Symbravo (meloxicam and rizatriptan). This treatment is for the acute treatment of migraine with or <a href="https://www.benzinga.com/pressreleases/25/01/g43351848/axsome-therapeutics-announces-fda-approval-of-symbravo-meloxicam-and-rizatriptan-for-the-acute-tre" target="_blank" rel="noreferrer noopener">without aura in adults</a>.
The company expects SYMBRAVO to be commercially available in the U.S. in approximately four months (June 2025).
Development Pipeline: 
AXS-05 (dextromethorphan-bupropion)
<ul>
<li>Alzheimer&#8217;s Disease Agitation: In March, Axsome received formal pre-NDA meeting minutes from the FDA for AXS-05 in AD agitation, supporting a supplemental NDA (sNDA) submission. The company is on track to submit the sNDA in the third quarter of 2025. </li>
<li>Smoking Cessation:&nbsp;Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in 2025.</li>
</ul>
<ul>
<li>Solriamfetol (dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist): In March, Axsome announced topline results from the FOCUS Phase 3 trial evaluating the efficacy and safety of solriamfetol in Attention Deficit Hyperactivity Disorder (ADHD) in adults. The company plans to initiate a Phase 3 trial of solriamfetol in ADHD in <a href="https://www.benzinga.com/25/03/44475435/axsome-therapeutics-lower-dose-of-attention-deficient-disorder-candidate-hits-primary-goal" target="_blank" rel="noreferrer noopener">pediatric patients in 2025</a>. </li>
<li>SYMBRAVO (MoSEIC meloxicam-rizatriptan): In February 2025, Axsome announced topline results from the EMERGE Phase 3 trial of Symbravo in migraine patients experiencing inadequate response <a href="https://www.benzinga.com/general/biotech/25/02/43921470/axsome-says-symbravo-hits-primary-goal-in-late-stage-migraine-trial-in-patients-experiencing-inadequate-response-to-commonly-used-drugs" target="_blank" rel="noreferrer noopener">to oral CGRP inhibitors</a>. </li>
<li>AXS-12 (reboxetine): Axsome previously announced the completion of its clinical program of AXS-12 in patients with narcolepsy with cataplexy. The company anticipates submitting an NDA to the FDA in the second half of 2025. </li>
<li>AXS-14 (esreboxetine): Axsome has submitted an NDA to the FDA for AXS-14 for fibromyalgia. The company anticipates the FDA&#8217;s decision on acceptance of the filing in the second quarter of 2025. </li>
<li>In April, Axsome announced topline results from the PARADIGM Phase 3 proof-of-concept trial. The company plans to initiate a Phase 3 trial of solriamfetol in Major Depressive Disorder patients with excessive daytime sleepiness in 2025.</li>
</ul>
<h3 class="wp-block-heading">What&#8217;s Next</h3>
<ul>
<li>Axsome is conducting the ENGAGE Phase 3 study of solriamfetol in Binge Eating Disorder. The company anticipates topline results in 2026. </li>
<li>Axsome is conducting the SUSTAIN Phase 3 study in adults with Shift Work Disorder. Topline data is anticipated in 2026.</li>
</ul>
Price Action: AXSM stock is up 5.16% at $118 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45192411/netflix-stock-drops-as-trumps-proposed-tariffs-on-foreign-films-spark-concerns" target="_blank" rel="noreferrer noopener">Netflix And Other Streaming Stocks Slide As Trump&#8217;s Proposed Tariffs On Foreign Films Sparks Concern</a></li>
</ul>

Earnings

Guidance

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

WIIM

Axsome Therapeutics shares are trading higher after the company announced a better-than-expected Q1 financial results.

Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(1.33) by 48.87 percent. This is a 32 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $121.46 million which beat the analyst consensus estimate of $119.87 million by 1.33 percent. This is a 61.95 percent increase over sales of $75.00 million the same period last year.

Earnings Beats

Axsome Therapeutics Q1 Adj. EPS $(0.68) Beats $(1.33) Estimate, Sales $121.46M Beat $119.87M Estimate

ACEL

ADEA

ADUS

AESI

AMRC

AOMR

AORT

ARES

AROC

BCRX

BCSF

BFAM

BNTX

BRBR

BRCC

BWXT

CERT

CORT

CRBG

CRGY

CSTL

CTRA

DENN

DMRC

DORM

EKSO

ESCA

EVER

FANG

FRPT

GBDC

GECC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSIC

HSII

HSTM

IART

ICHR

INSP

IPAR

IRMD

JBTM

JELD

JRVR

LSCC

MATX

MYPS

NBIX

NGVT

NMFC

NSSC

NVTS

OCUL

OPAD

OTTR

PLMR

PLOW

PLTR

PLYA

PRAA

PRIM

RAIL

RAND

Earnings Scheduled For May 5, 2025

In the latest quarter, 28 analysts provided ratings for Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">16</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">11</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $177.11, a high estimate of $216.00, and a low estimate of $133.00. Marking an increase of 9.75%, the current average surpasses the previous average price target of $161.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1745956875_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Axsome Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$193.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$216.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$212.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$192.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$153.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$176.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$167.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Marc Goodman</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$143.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Axsome Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>About Axsome Therapeutics</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Understanding the Numbers: Axsome Therapeutics's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Axsome Therapeutics's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 66.04%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -63.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -99.94%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Axsome Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -13.26%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.38, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $190 to $193.

RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $193

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor initiated coverage on Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy rating and announced a price target of $45. Ionis Pharmaceuticals shares closed at $27.09 on Friday. <a href="https://www.benzinga.com/quote/ions/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Andrew Tsai initiated coverage on Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy rating and announced a price target of $200. Axsome Therapeutics shares closed at $98.86 on Friday. <a href="https://www.benzinga.com/quote/axsm/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst John Kilichowski initiated coverage on NETSTREIT Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) with an Overweight rating and announced a price target of $18. Netstreit shares closed at $15.28 on Friday. <a href="https://www.benzinga.com/quote/ntst/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Youssef Squali initiated coverage on Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Buy rating and announced a price target of $150. Reddit shares closed at $86.91 on Friday. <a href="https://www.benzinga.com/quote/rddt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Greg Renza initiated coverage on BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) with an Outperform rating and announced a price target of $312. BeiGene shares closed at $238.51 on Friday.  <a href="https://www.benzinga.com/quote/onc/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying RDDT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="414" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07113723/image-67-1024x414.png" alt="" class="wp-image-860270" style="width:465px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07113723/image-67-1024x414.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07113723/image-67-300x121.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07113723/image-67-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07113723/image-67.png 1442w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44665280/how-to-earn-500-a-month-from-walgreens-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Walgreens Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

Markets

IONS

NTST

RDDT

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Jefferies analyst Andrew Tsai initiates coverage on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy rating and announces Price Target of $200.

Jefferies Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $200

<ul>
<li>Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation&nbsp;</li>
<li>Presentation featuring network meta-analysis of SYMBRAVO versus oral CGRPs</li>
</ul>

Axsome Therapeutics Announced Multiple Presentations At The 2025 American Academy Of Neurology Annual Meeting

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $200 price target.

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $200 Price Target

Legal

Press Releases

SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT) Should Contact Grabar Law Office Today

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Financing

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

DCGO

DRVN

MRCY

VIRT

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Oppenheimer

HC Wainwright & Co.

Wells Fargo

Baird

RBC Capital

Screenshot 2024-07-10 at 9.08.28 PM

TNXP

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-02-24 at 12.03.42 AM

ABBV

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Comments

Axsome Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO